Stock Analysis

4SC (FRA:VSC) Is Carrying A Fair Bit Of Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know worries about.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much debt can sink a company. We note that 4SC AG (FRA:VSC) does have debt on its balance sheet. But is this debt a concern to shareholders?

Advertisement

Why Does Debt Bring Risk?

Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. Ultimately, if the company can't fulfill its legal obligations to repay debt, shareholders could walk away with nothing. While that is not too common, we often do see indebted companies permanently diluting shareholders because lenders force them to raise capital at a distressed price. Having said that, the most common situation is where a company manages its debt reasonably well - and to its own advantage. The first step when considering a company's debt levels is to consider its cash and debt together.

What Is 4SC's Debt?

As you can see below, at the end of June 2025, 4SC had €7.12m of debt, up from €3.20m a year ago. Click the image for more detail. However, it does have €5.43m in cash offsetting this, leading to net debt of about €1.69m.

debt-equity-history-analysis
DB:VSC Debt to Equity History October 15th 2025

How Strong Is 4SC's Balance Sheet?

We can see from the most recent balance sheet that 4SC had liabilities of €7.72m falling due within a year, and liabilities of €543.0k due beyond that. Offsetting this, it had €5.43m in cash and €1.0k in receivables that were due within 12 months. So it has liabilities totalling €2.83m more than its cash and near-term receivables, combined.

While this might seem like a lot, it is not so bad since 4SC has a market capitalization of €8.83m, and so it could probably strengthen its balance sheet by raising capital if it needed to. However, it is still worthwhile taking a close look at its ability to pay off debt. The balance sheet is clearly the area to focus on when you are analysing debt. But it is 4SC's earnings that will influence how the balance sheet holds up in the future. So when considering debt, it's definitely worth looking at the earnings trend. Click here for an interactive snapshot.

View our latest analysis for 4SC

Given its lack of meaningful operating revenue, 4SC shareholders no doubt hope it can fund itself until it has a profitable product.

Caveat Emptor

While 4SC's falling revenue is about as heartwarming as a wet blanket, arguably its earnings before interest and tax (EBIT) loss is even less appealing. Its EBIT loss was a whopping €7.5m. When we look at that and recall the liabilities on its balance sheet, relative to cash, it seems unwise to us for the company to have any debt. So we think its balance sheet is a little strained, though not beyond repair. We would feel better if it turned its trailing twelve month loss of €7.7m into a profit. So we do think this stock is quite risky. The balance sheet is clearly the area to focus on when you are analysing debt. But ultimately, every company can contain risks that exist outside of the balance sheet. Be aware that 4SC is showing 3 warning signs in our investment analysis , and 2 of those are concerning...

At the end of the day, it's often better to focus on companies that are free from net debt. You can access our special list of such companies (all with a track record of profit growth). It's free.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About DB:VSC

4SC

A biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany and internationally.

Low risk with weak fundamentals.

Advertisement